Comparison of safety and efficacy of silodosin versus mirabegron in medical expulsive therapy for lower ureteric stone: a prospective, open label and randomized controlled trial

Ira Sharma; Atal Sood; Kulbhushan Sharma; Sushma Sawaraj; Nitin Patiyal

doi:10.18203/2319-2003.ijbcp20243837

Authors

Ira Sharma Department of Pharmacology, DRRPGMC Kangra at Tanda, Himachal Pradesh, India
Atal Sood Department of Pharmacology, DRRPGMC Kangra at Tanda, Himachal Pradesh, India
Kulbhushan Sharma Department of Urology, DRRPGMC Kangra at Tanda, Himachal Pradesh, India
Sushma Sawaraj Department of Pharmacology, DRRPGMC Kangra at Tanda, Himachal Pradesh, India
Nitin Patiyal Department of Pharmacology, DRRPGMC Kangra at Tanda, Himachal Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20243837

Keywords:

Mirabegron, MET, Silodosin, Stone expulsion time

Abstract

Background: Urolithiasis the most common condition affecting genitourinary tract and affect 5 to 10% of population worldwide. Almost all ureteric stones are symptomatic, and patients need to receive immediate evaluation and pain relief treatment. Passage of stone is facilitated by medical expulsive therapy (MET). Overall, 71-98% for stones in the distal ureter that are 5 mm or smaller passes with MET while 29-98% for stones in the proximal ureter that are 5 mm or smaller passes with MET. Silodosin (alpha-1 adrenergic receptor antagonist) and mirabegron (β-3 agonist) were compared for stone expulsion and analgesic effects for symptomatic relief.

Methods: The study was conducted in the department of pharmacology and the department of urology at Dr. R. P. G. M. C., Kangra at Tanda Himachal Pradesh, India which is 700 bedded multispecialty tertiary health care from August 2023to May 2024 and follow-up was done for 4 weeks after initiation of treatment, to compare the safety and efficacy of silodosin versus mirabegron in medical expulsion therapy for lower ureteric stone of size≤10 mm in adults.

Results: In our study patients in silodosin treatment arm had a smaller number of colick episodes (mean 1.65±1.02) during MET as compared to group (mean 2.23±1.07) receiving mirabegron (p=0.011). Patients in silodosin group had significantly lower analgesic requirement (mean 2.10±1.58) as compared to patients in mirabegron (mean 3.30±1.96) which is also statistically significant (p=0.002). Patients in silodosin group had highly significant lower time for stone expulsion (mean 10.0±5.3) as compared to that in patients in mirabegron group (mean 15.7±7.1) (p=0.0004). Overall, incidence of side effects was similar in both groups.

Conclusions: Silodosin demonstrated superior efficacy over Mirabegron in terms of reducing colic episodes, analgesic requirement and stone expulsion time in the management of ureteric calculi. No significant adverse events were reported in either group during the study period

Metrics

Metrics Loading ...

References

Colella J, Kochis E, Galli B, Munver R. Urolithiasis/ nephrolithiasis: what’s it all about? Urol Nurs. 2005;25:427-48.

Trinchieri A. Epidemiology of urolithiasis. Arch Ital Urol Androl. 1996;68:203-50.

Hussain M, Lal M, Ahmed S, Zafar N, Naqvi SA, Abid-ul-Hassan Rizvi S. Management of urinary calculi associated with renal failure. J Pak Med Assoc. 1995;45:205-8.

Pendse AK, Singh PP. The etiology of urolithiasis in Udaipur (western part of India). Urol Res. 1986;14:59-62.

Stemler KM, Mysorekar IU. Infectious Diseases: Urinary Tract Infections (Bacterial). Ureter in Pathobiology of human dis 5th edition. 2014.

Segura JW, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, et al. Ureteral stones clinical guidelines panel summary report on the management of ureteral calculi. J Urol. 1997;158(5):1915-21.

Türk C, Knoll T, Petrik A, Sarica K, Straub M, Seitz C. Guidelines on urolithiasis. European association of urology. 2011. Available at: http://www.uroweb.org/gls/pdf/22%20Urolithiasis_LR.pdf. Accessed on 1 September 2014.

Canda AE, Turna B, Cinar GM, Nazli O. Physiology and pharmacology of the human ureter: Basis for current and future treatments. Urol Int. 2007;78:289-98.

Sasaki S, Tomiyama Y, Kobayashi S, Kojima Y, Kubota Y, Kohri K. Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology. 2011;77(3):762-e13.

Coelho A, Antunes-Lopes T, Gillespie J, Cvuz F. Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immuno- histochemical study. Neurourol Urodyn. 2017;36:1972-80.

Matsumoto R, Otsuka A, Suzuki T, Shinbo H, Mizuno T, Kurita Y, Mugiya S, Ozono S. Expression and functional role of β3‐adrenoceptors in the human ureter. Int J Urol. 2013;20(10):1007-14.

Rossi M, Roumeguere T. Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther. 2010;4:291-7.

Sebastianelli A, Russo GI, Kaplan SA, Mc Vary KT, Moncada I, Gravas S, et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/ overactive bladder: Comparison with placebo and tolterodine. Int J Urol. 2018;25:196-205.

Wanajo I, Tomiyama Y, Yamazaki Y, Kojima M. Ureteral selectivity of intravenous beta-adrenoceptor agonists in pig model of acute ureteral obstruction: comparison of KUL-7211, a selective beta2/beta3 agonist, with isoproterenol, terbutaline, and CL-316243. Urology. 2011;77:e1-6

Bayar G, Yavuz A, Cakmak S, Ofluoglu Y, Kilinc M, Kucuk E, Aydın M. Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled study Int Urol Nephrol. 2020;52(5):835-40.

Kader M, Sayed A, Sayed S, Razek M. Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones Int Urol Nephrol. 2024;56(5):1605-10.

Itoh Y, Okada A, Yasui T, Hamamoto S, Hirose M, Kojima Y, et al. Efficacy of selective α1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol. 2011;18(9):672-4.

Solakhan M, Bayrak O, Bulut E. Efficacy of mirabegron in medical expulsive therapy. Urolithiasis 2019;47(3):303-7.

Abdullah A, Gupta Y, Selvaraj S, Ganapathy R, Ilangovan A, Sivalingam S, et al. A Comparison Between Silodosin and Tamsulosin for Medical Expulsive Therapy of Distal Ureteric Calculus. Cureus 2023;15(10):e47008.

Brohi I, Bhatti M, Siyal R, Ali F, Kaimkhani Z, Laghari H. Efficacy of Alpha-Adrenergic Receptor Antagonists In The Treatment Of Distal Ureteric Stones: A Paediatric Study. J Ayub Med Coll Abbottabad. 2022;34(4):807-11.

Tang Q, Wang D, Zhou S, Tao R. Mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study World J Urol. 2021;39(12):4465-70.